Volume 16, Number 10—October 2010
Research
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
Scott K. Heysell
, Jane L. Moore, Suzanne J. Keller, and Eric R. Houpt
, Jane L. Moore, Suzanne J. Keller, and Eric R. HouptTable 2
Comparison of median serum concentration at 2 hours after medication administration as estimate of peak serum concentration levels and expected range, therapeutic drug monitoring, Virginia, USA, March 1, 2007–May 1, 2009*
| Medication | Median serum concentration, µg/mL (IQR) | Expected serum concentration range, µg/mL |
|---|---|---|
| Isoniazid | ||
| Daily | 1.9 (1.1–3.5) | 3–6 |
| Biweekly |
9.8 (2.8–11.2) |
9–18 |
| Rifampin daily and/or biweekly |
7.4 (2.5–11.4) |
8–24 |
| Ethambutol† |
2.5 (1.7–3.2) |
2–6 |
| Pyrazinamide† | 28.1 (26.5–33.2) | 20–50 |
*IQR, interquartile range.
†All patients with therapeutic drug monitoring levels obtained for ethambutol and pyrazinamide were taking weight-based daily doses of these medications.
